CRISPR Therapeutics
CRSP
Market cap $3.26B

37.77 USD

-0.01

0.03%

At close Apr 17, 4:00 PM EDT

After hours

37.88

+0.11

0.29%

1 day

-0.03%

5 days

9.67%

1 month

-11.79%

3 months

-6.81%

6 months

-21.79%

Year to date

-8.83%

1 year

-32.02%

5 years

-26.55%

10 years

168.06%

About: Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 393

Healthcare Biotechnology

0

Funds holding %

of 7,419 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5.77% more ownership

Funds ownership: 69.81% [Q3] → 75.59% (+5.77%) [Q4]

6% less first-time investments, than exits

New positions opened: 65 | Existing positions closed: 69

6% less repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 119

3% less funds holding

Funds holding: 409 [Q3] → 396 (-13) [Q4]

9% less capital invested

Capital invested by funds: $2.79B [Q3] → $2.54B (-$251M) [Q4]

11% less call options, than puts

Call options by funds: $81.6M | Put options by funds: $91.6M

20% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$32

15%

downside

Avg. target

$72

90%

upside

High target

$120

218%

upside

12 analyst ratings

7 positive

58%

4 neutral

33%

1 negative

8%

Needham Gil Blum 12% 1-year accuracy 19 / 157 met price target	122%upside $84	Buy Reiterated	9 Apr 2025
Citigroup Yigal Nochomovitz 12% 1-year accuracy 5 / 41 met price target	117%upside $82	Buy Maintained	18 Feb 2025
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target	15%downside $32	Underweight Maintained	14 Feb 2025
Evercore ISI Group Liisa Bayko 40% 1-year accuracy 4 / 10 met price target	162%upside $99	Outperform Upgraded	14 Feb 2025
Goldman Sachs Salveen Richter 11% 1-year accuracy 2 / 18 met price target	51%upside $57	Neutral Maintained	13 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 18 articles about CRSP published over the past 30 days

The Motley Fool

5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years

A "monster stock" might be one that frightens you by free-falling. Or it might alarm you with characteristics such as plummeting sales, shrinking profit margins, or surging debt.

5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

The Motley Fool

3 Magnificent Stocks That Could Double or More by 2030

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.

3 Magnificent Stocks That Could Double or More by 2030

The Motley Fool

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities.

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 8, 2025 12:45 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Gil Blum - Needham & Company Gil Blum Good afternoon, everyone, and thank you for joining me at the second day of the Needham Healthcare conference. My name is Gil Blum, and I am senior biotech analyst here at Needham & Company with a focus on immune-oncology.

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

The Motley Fool

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

It's shaping up to be another rocky week of trading, and the volatility will probably keep Cathie Wood busy. The co-founder, CEO, and ace stock picker for Ark Invest tends to be active when the market's moving one way or another.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The Motley Fool

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™